Combination therapy

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

So far, off-label recommendation of a combination therapy is mainly based on phase II study evidence and on largely accepted expert opinions. Combination therapy represents a new, more global strategy, to increase the possible benefits with the combined use of already available disease-modifying therapies or with other new agents, having an acceptable theoretical rationale and a good safety and efficacy profile. The therapeutic strategies of the near future will try to select among different and individualised combinations of drugs, with distinct mechanisms of action, and possibly with synergistic activity, to maximise benefits and minimise risks. The combination approach is at present particularly recommended for more aggressive forms of multiple sclerosis (MS) and for non-responders to available drugs, although the theoretical rationale and accumulated experience would suggest its use in all MS patients right from the beginning of the disease.

Original languageEnglish
JournalNeurological Sciences
Volume27
Issue numberSUPPL. 5
DOIs
Publication statusPublished - Sep 2006

Fingerprint

Multiple Sclerosis
Expert Testimony
Patient Rights
Drug Combinations
Therapeutics
Safety
Pharmaceutical Preparations

Keywords

  • Combination therapy
  • Immunomodulatory agents
  • Immunosuppressive agents
  • Induction therapy
  • Multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Combination therapy. / Martinelli, Vittorio.

In: Neurological Sciences, Vol. 27, No. SUPPL. 5, 09.2006.

Research output: Contribution to journalArticle

Martinelli, Vittorio. / Combination therapy. In: Neurological Sciences. 2006 ; Vol. 27, No. SUPPL. 5.
@article{cf67ca7662b44db9a96db1ba667ab53a,
title = "Combination therapy",
abstract = "So far, off-label recommendation of a combination therapy is mainly based on phase II study evidence and on largely accepted expert opinions. Combination therapy represents a new, more global strategy, to increase the possible benefits with the combined use of already available disease-modifying therapies or with other new agents, having an acceptable theoretical rationale and a good safety and efficacy profile. The therapeutic strategies of the near future will try to select among different and individualised combinations of drugs, with distinct mechanisms of action, and possibly with synergistic activity, to maximise benefits and minimise risks. The combination approach is at present particularly recommended for more aggressive forms of multiple sclerosis (MS) and for non-responders to available drugs, although the theoretical rationale and accumulated experience would suggest its use in all MS patients right from the beginning of the disease.",
keywords = "Combination therapy, Immunomodulatory agents, Immunosuppressive agents, Induction therapy, Multiple sclerosis",
author = "Vittorio Martinelli",
year = "2006",
month = "9",
doi = "10.1007/s10072-006-0692-x",
language = "English",
volume = "27",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "SUPPL. 5",

}

TY - JOUR

T1 - Combination therapy

AU - Martinelli, Vittorio

PY - 2006/9

Y1 - 2006/9

N2 - So far, off-label recommendation of a combination therapy is mainly based on phase II study evidence and on largely accepted expert opinions. Combination therapy represents a new, more global strategy, to increase the possible benefits with the combined use of already available disease-modifying therapies or with other new agents, having an acceptable theoretical rationale and a good safety and efficacy profile. The therapeutic strategies of the near future will try to select among different and individualised combinations of drugs, with distinct mechanisms of action, and possibly with synergistic activity, to maximise benefits and minimise risks. The combination approach is at present particularly recommended for more aggressive forms of multiple sclerosis (MS) and for non-responders to available drugs, although the theoretical rationale and accumulated experience would suggest its use in all MS patients right from the beginning of the disease.

AB - So far, off-label recommendation of a combination therapy is mainly based on phase II study evidence and on largely accepted expert opinions. Combination therapy represents a new, more global strategy, to increase the possible benefits with the combined use of already available disease-modifying therapies or with other new agents, having an acceptable theoretical rationale and a good safety and efficacy profile. The therapeutic strategies of the near future will try to select among different and individualised combinations of drugs, with distinct mechanisms of action, and possibly with synergistic activity, to maximise benefits and minimise risks. The combination approach is at present particularly recommended for more aggressive forms of multiple sclerosis (MS) and for non-responders to available drugs, although the theoretical rationale and accumulated experience would suggest its use in all MS patients right from the beginning of the disease.

KW - Combination therapy

KW - Immunomodulatory agents

KW - Immunosuppressive agents

KW - Induction therapy

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=33749137775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749137775&partnerID=8YFLogxK

U2 - 10.1007/s10072-006-0692-x

DO - 10.1007/s10072-006-0692-x

M3 - Article

C2 - 16998718

AN - SCOPUS:33749137775

VL - 27

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - SUPPL. 5

ER -